



Signalife

Clear Data. Trusted Results.

Signalife, Inc.
531 South Main St. ~ Suite 301
Greenville, SC 29601
T 864.233.2300
F 864.233.2100
www.signalife.com
info@signalife.com

PRESS RELEASE

Tuesday October 26, 2004 | 9:41 am ET

Recom's Heart Monitor Clears Safety Test Heart Monitor Now Ahead of Schedule for Worldwide Commercial Product Rollout

STUDIO CITY, Calif.—(BUSINESS WIRE)—Oct. 26, 2004—Recom Managed Systems, Inc. (OTCBB: RECM - News), a leader in innovative design and development of ambulatory diagnostic devices which utilize the company's proprietary signal processing technology, announced today that its Model 100 has successfully completed and passed its initial safety tests. The results of these tests show Recom's Model 100 meets the stringent Federal Communications Commission (FCC) requirements for Human Exposure to Radiofrequency (RF) and the Food and Drug Administration's (FDA) voluntary consensus standards for electromagnetic compatibility (EMC). Recom anticipates it will complete its second series of tests in November and, if successful, will allow for the commercialization of the Model 100 ambulatory ECG diagnostic device in the first quarter of 2005.

Bill Matthews, responsible for regulatory affairs at the company, commented: "We have achieved another critical step necessary to enabling us to begin marketing our Model 100. In meeting the FCC standards, not only have we reached another benchmark toward distribution in the United States, but we have also achieved compliance with international requirements regarding human exposure to RF Electromagnetic Fields."

Marvin Fink, Recom's President, added: "As the test results come in we are pleased with the outcome. The Model 100 is performing better than anticipated and thanks to the efforts of our internal development team and Battelle Memorial Institute we are ahead of schedule for our initial product rollout."

Recom's Model 100 was tested by RF Exposure Laboratory of Escondido, California, to FCC Office of Engineering and Technology (OET) Bulletin 65 Supplement C for General Population/Uncontrolled Exposure. The testing standards are some of the most stringent and are intended to protect the user and general public from the affects of RF exposure. With regard to the voluntary FDA consensus standards for EMC, the Model 100 was tested by Nemko USA of Sand Diego, California. Nemko USA tested the Model 100 for compliance with IEC 60601-1-2:2001 (Medical Electrical Equipment Part 1:2-General Safety Requirements for Safety, Collateral Standard: Electromagnetic Compatibility Requirements and Tests). These standards are intended to reduce the risk of EMC and the interference that electromagnetic fields can cause. With regard to the second and final series of tests, they are being conducted by Nemko USA for compliance with IEC 60601-1(Medical Electrical Equipment Part 1: General Requirements for Safety), UL 60601-1 and CAN/CSA 22.2-601.1. Upon successful meeting these final requirements, Recom's Model 100 will address the safety requirements for the United States, Canada, and the European Union.

About Recom Managed Systems, Inc.

Recom Managed Systems, Inc. is an emerging life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Recom Managed Systems, Inc. uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. With our patented signal technology platform, Recom brings clinical quality physiological signal monitoring to the ambulatory setting.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are “forward-looking” statements. Forward-looking statements involve known and unknown risks, which may cause Recom’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approvals governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Recom’s products or services, adverse equity market conditions and declines in the value of Recom’s common stock, and the unavailability of financing to complete management’s plans and objectives. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Recom’s filings with the Securities and Exchange Commission.

Contact:

Recom Managed Systems, Inc.
Rodney Hildebrandt, 864-233-2300
Fax: 864-233-2100

Source: Recom Managed Systems